Hengeler Mueller advises Founder of APOSAN on sale of APOSAN to funds advised by IK Investment Partners
05. October 2016
The Cologne based health care company APOSAN Dr. Künzer GmbH (APOSAN) has been sold by its founder and sole shareholder to funds advised by IK Investment Partners. The company is primarily engaged in the production of patient-individual sterile infusions for outpatient treatment. Other areas of activity include the production of patient-individual parenteral nutrition, and of prescription drugs in sterile ready-to-use syringes used for ophthalmic surgeries. The transaction is subject to customary closing conditions.
Hengeler Mueller advised the founder and sole shareholder of APOSAN on the transaction. The team was led by Thomas Meurer and Carsten Schapmann (Corporate/M&A) and included partners Alf-Henrik Bischke (Competition), Dirk Uwer (Regulatory, all Düsseldorf), Matthias Scheifele (Tax, Frankfurt), Christian Schwandtner (Corporate/M&A, Düsseldorf) and Hendrik Bockenheimer (Labour, Frankfurt) as well as associates Peter Wehner (Labour), Claudia Nees (Tax, both Frankfurt), Deniz Tschammler (Regulatory) Katharina Hesse and Ute König (both Corporate/M&A, all Düsseldorf).